This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients withmyelodysplastic syndromes who failed previous therapy. Sometimes when chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to treatment. 6, 8-bis (benzylthio) octanoic acid may interfere with the growth of tumor cells and may be an effective treatment formyelodysplastic syndromes that did not respond to previous therapy.
Clinical Trial: NCT01902381
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy